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ABSTRACT
Sulphur mustard (SM) is a chemical warfare agent that causes serious blisters upon contact
with human skin.  SM alkylates DNA and several other macromolecules, and also induces oxidative
stress.  Quercetin, a bioflavonoid has wide pharmacological actions. The protective efficacy of
quercetin (100 mg/kg, i.p. and 200 mg/kg, i.p.) was studied by administering three doses in mice
against SM.  The first dose was administered at 30 min prior, simultaneous, 2 h post or 24 h post,
and two more doses on the next two days.  SM was administered (in PEG 300) percutaneously
at varying doses for survival and protection studies.  SM was also administered at a dose of
2 LD50 (19.3 mg/kg) with and without quercetin treatment and various biochemical markers were
estimated 7 days after SM administration.  Histological examinations of vital organs were also
carried out. The animals administered with SM died at various days depending upon the dose.
The body weight decreased significantly. Quercetin protected the mice significantly, in a dose-
dependent manner. The protection was better when the first dose of quercetin administered was
30 min prior or simultaneously.  A significant decrease in reduced as well as oxidised glutathione
and an increase in malondialdehyde, WBC count, RBC count, and haemoglobin were observed
with 2 LD50 SM. Quercetin at 100 mg/kg and 200 mg/kg doses significantly protected the biochemical
markers when the first dose of quercetin administered was 30 min prior or as simultaneous
treatment.  The histological lesions induced by sulphur mustard on liver, spleen, and skin were
also significantly protected by quercetin when the first dose was administered 30 min prior or
as simultaneous treatment. The present study shows that percutaneous administration of SM
induces oxidative stress and quercetin can protect it as a prophylactic agent.
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1 . INTRODUCTION
The organophosphorus nerve agents and the
blistering agents continue to be threats not only as
chemical warfare agents, but also from the terrorist
organisations. Though the Chemical Weapons
Convention is signed and ratified by several countries
and the stockpiled chemical warfare agents are
being destroyed, still the threat persists from the
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use of chemical weapons. The mechanism of action
of the nerve agents is clearly understood and effective
and accepted treatment protocols are known1. In
spite of research over several decades, no satisfactory
prophylactic or treatment regimen has evolved for
sulphur mustard (SM), a well known blistering agent.
So the search for a better antidote is being pursued
the world over.
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The SM, commonly known as mustard gas, is
chemically bis (2-chloroethyl) sulphide and an alkylating
agent that causes serious blisters upon contact
with human skin. SM has been used as a chemical
warfare agent in many instances2-5. SM forms
sulphonium ion in the body and alkylates DNA
leading to DNA strand breaks and cell death6. Due
to the high electrophilic property of the sulphonium
ion, SM binds to a variety of cellular macromolecules7.
Eyes, skin and the respiratory tract are the principal
target organs of SM toxicity6,8.
Antidotes to SM can act by four different
mechanisms:
(a) Prevention of SM from entering the system
(personal decontamination at the site of contact),
(b) Prevention of SM from alkylating critical target
molecules mainly DNA,
(c) Retrieval of SM alkylated DNA
(d) Prevention and reversal of the cascade of secondary
biochemical reactions of alkylation6-9.
Several antidotes have been reported for reducing
the systemic toxicity of SM in experimental animals9-15.
Most of the antidotes are in various stages of
development and so far none recommended. One
of the interesting findings is that percutaneously
administered SM is more toxic than subcutaneous
and oral routes of administrations16. The most effective
way of minimising SM toxicity is by decontamination
either by physical adsorption or by chemical
decontamination17.
One of the important mechanisms of action of
SM cytotoxicity is based on the depletion of reduced
glutathione (GSH), and subsequent lipid peroxidation
and free radical generation7,18. Flavonoids are reported
to exhibit a wide variety of biological effects, including
antioxidant and free radical scavenging activities.
Quercetin and other flavonoids have been shown
to modify eicosanoid biosynthesis (antiprostanoid
and anti-inflammatory responses), protect low-density
lipoprotein from oxidation (prevent atherosclerotic
plaque formation), prevent platelet aggregation
(antithrombic effects), and promote relaxation of
cardiovascular smooth muscle (antihypertensive,
antiarrhythmic effects). In addition, flavonoids have
been shown to have antiviral and carcinostatic
properties19. Ethanol-induced oxidative stress was
protected by pre-treatment with quercetin by directly
quenching lipid peroxides and indirectly by enhancing
the production of the endogenous antioxidant GSH20,21.
Protective effect of quercetin on carbon tetrachloride-
induced hepatotoxicity, cyclosporin-induced
nephrotoxicity, and cisplatin-induced cytotoxicity
in cultured tubular epithelial cells have been
reported22-24. Quercetin was effective in protecting
silica-induced cell injury due to its antiradical
property25. The study was aimed to evaluate the
protective effect of quercetin against percutaneously
administered SM.
2 . MATERIALS AND METHODS
2.1 Chemicals
Quercetin dihydrate was purchased from Aldrich
Chemical Company (USA). SM was synthesised
in the declared facility of the Establishment and
was found to be above 99 per cent pure by gas
chromatographic analysis. All other chemicals used
were of analytical grade.
2.2 Animals
Randomly bred Swiss female mice (25 g to 30 g
body weight) maintained in the Establishment's animal
house were used for the study. The animals were
housed in polypropylene cages on dust-free rice
husk as the bedding material. The animals were
provided with pellet diet (Amrut Ltd, India) and
water ad libitum. This study was approved by the
Ethical Committee of the Establishment. A day
before dermal application of SM, the hair on the
back of mice were closely clipped using a pair of
scissors.
2.3 Protection Studies on Animal Mortality
The SM was applied in varying doses on groups
of mice and quercetin was administered intraperitoneally
(i.p.) as three injections with the first injection
given at 30 min prior, simultaneous (0 min), 2 h post
or 24 h post. The remaining two doses of quercetin
were given on the next two days. Two doses of
quercetin used were 100 mg/kg and 200 mg/kg by
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dissolving in polyethylene glycol (PEG 300). SM
was diluted in PEG 300 and applied on the back
of mice. The dilutions were made in such a manner
that the quantity applied was not more than 100 l.
The animals were weighed daily and observed for
mortality for a period of 14 days. Each group
consisted of four mice per dose, and 3 to 4 log
doses were used.
In another study, mice were administered with one
intraperitoneal injection of quercetin (100 mg/kg and
200 mg/kg), either 30 min prior or simultaneous, and
various doses of SM were applied percutaneously to
find the effect of a single injection as prophylactic dose.
2.4 Protection Studies on Biochemical
Variables
To evaluate the protective effect of quercetin
on the GSH, GSSG, MDA, and DNA fragmentation,
the following groups were kept:
diluted in PEG 300 and applied on the back of
mice. The dilutions were made in such a manner
that the quantity applied was not more than 0.1 ml.
Blood was withdrawn from ocular plexus under
ether anaesthesia and the animals were sacrificed
by cervical dislocation, seven days after SM application.
Each group consisted of four mice. The blood was
used for the measurement of RBC and WBC counts
and haemoglobin estimation. Pieces of liver were
removed, blotted, weighed and used for the estimation
of GSH, GSSG, and MDA. Pieces of liver, spleen
and skin (on the site of SM application) were also
removed for light microscopic studies.
The fluorometric method of Hisin and Hilf26
was used for the determination of hepatic GSH,
and GSSG concentration. For this, 150 mg of liver
tissue was homogenised in 4 ml of phosphate EDTA
buffer and metaphosphoric acid (25 %). The content
of the tube was centrifuged and the supernatant
was used for the estimation of GSH and GSSG.
Hepatic lipid peroxidation was determined by measuring
the level of MDA according to the method of
Buege and Aust27. One hundred milligram of liver
was directly homogenised in 5 ml of thiobarbituric
acid reagent and boiled for 30 min. The contents
of the tube were cooled, centrifuged, and absorbance
of the clear supernatant was measured at 535 nm.
The amount of MDA formed was calculated using
a molar extinction coefficient of 1.58 x 105/M
per cm. DNA fragmentation assay was carried out
as per the method of McConkey28, et al. Briefly,
the frozen liver samples were homogenised in ice
cold lysis buffer (10 mM tris, 20 mM EDTA, 0.5
% triton-x-100, pH 8) and then centrifuged at 27,000
g for 30 min. Both pellet (intact chromatin) and
supernatant (DNA fragments) were assayed for
DNA content, using diphenylamine29. The percentage
of fragmented DNA was defined as the ratio of
DNA content of supernatant at 27,000 g to the
total DNA in the lysate30. The other haematological
variables, viz., RBC and WBC counts and blood
haemoglobin were analysed using Beckman Coulter
Cell Counter (USA).
2.5 Protection Studies on Histological Lesions
The excised skin portion was removed and
stretched in the wax tray and immersed in 10 per
I. Distilled water,  i.p.  + PEG 300 dermal (control group)
 
II. PEG 300, i.p.  + SM (19.3 mg.kg-1) in PEG 300 
dermal (LD50 of SM = 9.7 
mg/kg;  SM group) 
III. Quercetin (100 mg/kg, 
i.p.) 30 min prior SM 
+ SM (19.3 mg.kg-1) in PEG 300 
dermal 
IV. Quercetin (200 mg/kg, 
i.p.) 30 min prior SM 
+ SM (19.3 mg.kg-1) in PEG 300 
dermal 
V. Quercetin (100 mg/kg, 
i.p.) simultaneously 
with SM 
+ SM (19.3 mg.kg-1) in PEG 300 
dermal 
VI. Quercetin (200 mg/kg, 
i.p.) simultaneously 
with SM 
+ SM (19.3 mg.kg-1) in PEG 300 
dermal 
VII. Quercetin (100 mg/kg, 
i.p.) 2 h post SM 
+ SM (19.3 mg.kg-1) in PEG 300 
dermal 
VIII. Quercetin (200 mg/kg, 
i.p.) 2 h post SM 
+ SM (19.3 mg.kg-1) in PEG 300 
dermal 
IX. Quercetin (100 mg/kg, 
i.p.) 24 h post SM 
+ SM (19.3 mg.kg-1) in PEG 300 
dermal 
X. Quercetin (200 mg/kg, 
i.p.) 24 h post SM 
+ SM (19.3 mg.kg-1) in PEG 300 
dermal 
Three injections of quercetin were administered
intraperitoneally, with the first injection given at
30 min prior, treatment simultaneous (0 min), 2 h
post or 24 h post-treatment. The remaining two
doses were given on the next two days. SM was
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cent neutral buffered formalin (pH 7.2) for 4 h.
After proper hardening, the skin tissue was chopped
into small pieces and fixed in fixative for another
24 h. Hepatic and splenic tissues were removed,
pruned, blotted, and weighed. These tissues were
fixed in 10 per cent buffered formalin. After proper
fixation, small pieces of the tissues were processed
by dehydration and embedded in paraffin wax.
Multiple sections from each block were prepared
of 5-6 m thickness and stained with hematoxylin
and eosin for microscopic observation31. From each
tissue 10 slides were prepared. Out of the 60 slides
(6 animals), six slides were selected for lesion
evaluation. From each of the selected slides, 90 m2 area
was identified randomly and lesions were marked
and compared with that of control. The severity of
lesions was characterised using LEICA-QWIN-
500 image analyser and converted into percentage.
The lesions were observed under microscope,
characterised and scored using LEICA-QWIN-500-
IW image analyser.
2.6 Statistical Analysis
LD50 and confidence intervals were determined
by the moving average method32. If the confidence
intervals could not be determined due to per cent
and 100 per cent mortality in subsequent doses,
then the doses producing 0 per cent and 100 per
cent mortality were taken as lower and upper limits
of confidence interval, respectively. The biochemical
parameters were analysed by one-way ANOVA
with Dunnett's multiple comparisons procedure. A
probability of < 0.05 is taken as statistically significant.
SigmaStat (SPSS Inc, USA) was used for the statistical
analyses.
3 . RESULTS
The animals administered with SM died at various
days depending upon the dose. The LD50 of SM
by percutaneous route was found to be 9.7 mg/kg.
Quercetin protected the mice significantly, in a
dose-dependent manner. The protection was seen
only when quercetin was given either as 30 min
prior or simultaneous treatment. Single dose as well as
three doses given in these groups protected the mice
and the protection was more or less similar (Table 1).
The body weight of mice administered with
19.3 mg/kg (2 LD50) decreased significantly compared
to the control group. Quercetin protected the decrease
in body weight significantly, in a dose-dependent
manner. The protection was better when the first
dose of quercetin administered was 30 min prior
or simultaneous. Significant protection was observed
when quercetin was given either as a single dose
or as three doses (Table 2).
The control group values of reduced glutathione
was found to be 3.50 ± 0.10 moles/g of liver, oxidised
glutathione was found to be 1.86 ± 0.33 moles/g of
liver, malondialdehyde level was found to be 3.86 ±
0.10  moles/g of liver. There was a significant decrease
in GSH as well as GSSG content and an increase
in MDA following SM application (Table 3). Quercetin
100 mg/kg and 200 mg/kg doses significantly protected
Group 
(First dose of quercetin) 
Quercetin 100 mg/kg 
LD50 (mg/kg) (confidence limit) 
PI Quercetin 200 mg/kg 
LD50 (mg/kg) (confidence limit) 
PI No. of doses of 
quercetin 
SM only 9.7 
(6.1 - 15.2) 
- - - - 
 
30 min + SM 19.3 
(7.3 - 51.4) 
2.0 38.6 
(14.8 - 100.3) 
4.0 3 
0 min + SM 19.3 
(10.6 - 35.3) 
2.0 78.0 
(27.6 - 220.1) 
8.0 3 
+  2 h + SM 9.7 
(5.9 - 15.8) 
1.0 9.7 
(5.9 - 15.8) 
1.0 3 
+ 24 h + SM 8.1 
(0.2 - 12.4) 
0.8 8.1 
(0.2 - 12.4) 
0.8 3 
30 min + SM 38.6 
(22.2 - 67.3) 
4.0 78.0 
(27.6 - 220.1) 
8.0 1 
0 min + SM 30.7 
(21.6 - 43.5) 
3.2 54.6 
(15.2 - 196.5) 
5.6 1 
Protection Index (PI) = Ratio of LD50 with treatment to LD50 without treatment 
Table 1. Protective effect of quercetin against percutaneously administered sulphur mustard
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the decrease in GSH and GSSG, and an increase in
MDA induced by SM, when the first dose of quercetin
administered was 30 min prior or simultaneous. The
percent DNA fragmentation was increased following
SM application and quercetin at a dose of 200 mg/kg,
significantly protected the DNA damage when it was
administered 30 min prior or simultaneous (Table 3).
There was no significant change in the WBC
count after SM administration. Significant increase
in RBC count and haemoglobin content was observed
after percutaneous administration of SM. Quercetin
administered as either 30 min pre-treatment or as
simultaneous treatment significantly protected them
(Table 4).
Group 
(First dose of quercetin) 
WBC (%) 
100 mg/kg           200 mg/kg 
RBC (%) 
100 mg/kg           200 mg/kg 
HB (%) 
100 mg/kg           200 mg/kg 
Control 99.6 ± 9.7 - 102.9 ± 2.4  -  102.6 ± 3.3  - 
Only SM 119.2 ± 15.3 - 130.9 ± 2.4a  -  120.1 ± 8.6  - 
 30 min + SM 84.9 ± 11.5 119.2 ± 15.3 106.4 ± 2.2b 103.5 ± 2.7b 103.5 ± 2.8 99.9 ± 1.7 
0 min + SM 109.4  ± 7.1 108.6 ± 12.3 106.1 ± 4.1b 103.5 ± 3.9b 103.7 ± 2.0 100.8 ± 2.7 
+ 2 h + SM 93.3 ± 10.7 104.2 ± 5.2 126.4 ± 7.0a 125.8 ± 4.0a 129.6 ± 11.1a 131.5 ± 11.3a 
+ 24 h + SM 92.4 ± 23.0 126.4 ± 13.6 126.4 ± 5.7a 138.2 ± 4.0a 124.9 ± 5.7 136.7 ± 6.1a 
Mean ± SE (n = 4) 
WBC = 13.4 ± 0.7 x 103 cells/ l;  RBC = 8.4 ± 0.4 x 106 cells/ l;  Hb =  13.2 ±  0.4 g/dl  
Significance P < 0.05 : a - Control versus treatment;  b -  SM versus treatment         
*Quercetin 3 doses. 
 
Table 4. Effect of 2 LD50 of percutaneously administered SM on WBC, RBC and haemoglobin of blood, and protection by
quercetin*
Group 
(First dose of quercetin) 
Quercetin  
3 doses (i.p.) 
100 mg/kg 
1 dose 
Quercetin  
3 doses (i.p.) 
200 mg/kg 
1 dose 
Control 98.7 ± 1.3 - - - 
SM only 58.7 ± 1.5a - - - 
30 min + SM 91.1 ± 3.8b 68.2 ± 3.4a 94.0 ± 3.1b 89.1 ± 5.6b 
   0 min + SM 89.1 ± 2.5b 82.9 ± 5.2ab 86.8 ± 4.9b 91.8 ± 5.6b 
+ 2 h + SM 70.0 ± 6.9a 64.9 ± 3.5a 68.6 ± 4.4ab 70.3 ± 0.6ab 
+ 24 h + SM 66.7 ± 4.3a - 70.6 ± 1.2ab - 
Mean ± SE (n = 4) 
Significance (P < 0.05)  a - Control versus treatment;   b - SM versus treatment 
Biochemical and histological studies were carried out in mice administered with three injections of quercetin.  
Table 2 . Percent change in body weight, seven days after 2 LD50 of percutaneously administered SM and protection by quercetin
Group (First dose of 
quercetin) 
MDA (%) 
Quercetin 
GSH (%) 
Quercetin 
GSSG (%) 
Quercetin 
DNA frag. (%) 
Quercetin 
100 mg/kg 200 mg/kg 100 mg/kg 200 mg/kg 100 mg/kg 200 mg/kg 200 mg/kg 
Control 99.9 ± 1.7 - 99.7 ± 2.6 - 99.2 ± 3.0  - 28.9 ± 0.2 
Only SM 149.6 ± 8.5a - 46.1 ± 1.4a - 55.0 ± 0.3a  - 47. ± 3.9a 
30 min + SM 97.0 ± 5.7b 94.7 ± 3.4b 62.6 ± 7.3a  77.7 ± 6.6ab 85.8 ± 7.9b 91.6  ± 5.0b 31.1 ± 3.2b 
0 min + SM 108.3 ± 2.5b 100.7 ± 4.1b 84.9 ± 8.8b  101.6 ± 11b 103.4 ± 9.4b 94.8 ± 3.5b 32.7 ± 1.6b 
+ 2 h + SM 124.2 ± 6.5ab 104.2 ± 5.2b 40.2 ± 3.8a  53.5 ± 3.8a 50.5 ± 5.2a 55.8 ± 5.9a 56.1 ± 5.8a 
+24 h + SM 115.0 ±  1.5b 126.5 ± 13.6b 35.5 ± 2.9a  47.3 ± 2.3a 45.2 ± 1.8a 55.5 ± 6.5a - 
Mean ± SE (n = 4) 
MDA = 3.86  ± 0.10 n moles/g tissue; GSH = 3.50 ± 0.1 moles/g tissue; GSSG = 1.86 ± 0.33  moles/g tissue 
Significance P < 0.05 a - Control versus treatment;  b -  SM versus treatment         
*Quercetin 3 doses (i.p.). 
Table 3. Effect of 2 LD50 of percutaneously administered SM on MDA, GSH and GSSG of liver and protection by quercetin*
712
DEF SCI J, VOL. 57, NO. 5, SEPTEMBER 2007
,
Figure 1. Photomicrographs of mice spleen; H and E, 100x: (a) control spleen showing normal histology of germinal centre,
red and white pulp follicles, (b) SM-administered mice spleen (2 LD50) showing congestion, hypocellularity and
parenchymal atrophy, (c and d) pre- and simultaneous treatment respectively of 100 mg/kg of quercetin with SM, and
(g and h) pre- and simultaneous treatment respectively of 200 mg/kg of quercetin with SM, showing near normal
histology of spleen, (e and f) 2 h and 24 h post-treatment respectively of quercetin 100 mg/kg with SM, and (i and
j) 2 h and 24 h post-treatment respectively of quercetin 200 mg/kg with SM, showing occasional haemorrhagic foci
and necrotic red pulp follicles in the spleen.
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Spleen histology of control mice showed normal
structure having white pulp, red pulp, germinal
centre and periarteriolar lymphatic sheath (PALS)
[Fig. 1(a)]. Histological observation of spleen of
mice, treated with SM showed severe congestion
and hypocellularity of white pulp follicles. The
spleen capsule was occasionally detached from
the underlying parenchyma. This was partly caused
by parenchymal atrophy and degenerative changes
in the extracellular space leading to an overall
shrinkage of the parenchyma and hypocellularity
[Fig. 1(b)]. Quercetin at a dose of 100 mg/kg and
200 mg/kg doses reduced the severity of the lesions.
Pre-treatment for 30 min and simultaneous treatment
of quercetin showed near-normal histology [Figs
1(c), 1(d), 1(g) and 1(h)]. Occasional small foci
of haemorrhage and necrosis remained in the red
pulp of spleen in the 2 h and 24 h post-treatment
groups of quercetin [Figs 1(e), 1(f), 1(i) and 1(j)].
Post-treatment for 24 h showed the least recovery,
with similar but more severe pathologies than the
post-treatment of quercetin for 2 h. A comprehensive
account of various histopathological lesions in the
splenic parenchyma and their protection by simultaneous
treatment of quercetin is shown in Table 5.
Lesion SM  SM 
quercetin 
100 mg/kg 
SM 
quercetin 
200 mg/kg
 
White pulp hypocellularity +++ ++ ++ 
Atrophy of PALS +++ + + 
Congestion and haemorrhage +++ + + 
Activation of megakaryocytes ++ + + 
Condensation of chromatin ++++ ++ + 
Necrosis/Apoptosis ++++ ++ ++ 
Accumulation of fibrinoid 
material 
+++ + + ++ 
Grading :     - nil, + minimal (< 12 %), ++ mild (< 22 %), 
+++ moderate (< 45 %) and ++++, severe (> 45 %). 
The animals were sacrificed 7 days after SM administration. Quercetin 
was given as three doses with the first dose given simultaneously and two 
more doses on the subsequent days. 
Table 5. Splenic lesions induced by percutaneously
administered SM at a dose of 2 LD50 and its
protection by simultaneous treatment of quercetin
degeneration and perinuclear clumping of cytoplasm.
Vacuolar degeneration of hepatocytes was predominantly
observed in the intermediate zone with vacuolisation
of centrilobular zone. The prominent lesions were
cell swelling, cytoplasmic vacuole formation, and
accumulation of inflammatory cells composed of
lymphocytes and mononuclear cells. Sporadic neutrophils
were also observed in the degenerated hepatic
parenchyma [Fig. 2(b)]. The severity of the lesions
was markedly reduced with quercetin administration
at 30 min pre-treatment and simultaneous treatment
at a dose of 100 mg/kg and 200 mg/kg. However,
there was occasional vacuolar degeneration, nuclear
pyknosis/necrosis and vascular congestion [Figs
2(c), 2(d), 2(g) and 2(h)]. The protective effect of
100 mg/kg and 200 mg/kg of quercetin given
simultaneously with SM is shown in Table 6. Post-
treatment for 2 h and 24 h of quercetin did not
reduce the severity of the hepatic lesions [Figs
2(e), 2(f), 2(i) and 2(j)].
The histology of control mouse skin consisted
of the three layers, viz., epidermis, dermis and
hypodermis. The epidermis was thin and consisted
of three layers dark stained outermost stratum
cornium layer having flattened fused cells devoid
of organelles, stratum granulosum comprising dense
basophilic granular cells, and stratum spinosum
Table 6. Hepatic lesions induced by percutaneously
administered SM at a dose of 2 LD50 and its
protection by simultaneous treatment of quercetin
Lesions SM  SM 
quercetin 
100 mg/kg 
SM 
quercetin 
200 mg/kg
Disturbed lobular pattern ++ ++ + 
Haemorrhage +++ + ++ 
Necrosis/apoptosis +++ ++ ++ 
Obliteration of chromatin +++ ++ ++ 
Proliferation of bile duct 
parenchyma 
+++ + ++ 
Clumping of cytoplasm  ++++ ++ ++ 
Hepatic vacuolation  ++++ ++ ++ 
PMN. infiltration ++ - + 
Grading : - nil, + minimal (< 12 %), ++ mild (< 22 %),  
+++ moderate (< 45 %) and ++++, severe (> 45 %). 
The animals were sacrificed seven days after SM administration. 
Quercetin was given as three doses with the first dose given 
simultaneously and two more doses on the subsequent days. 
Histological features of control mice showed
normal hepatic chord, hepatic lobules and hepatocytes
[Fig. 2(a)]. Liver histology of mice after SM
administration revealed hepatocellular cytoplasmic
vacuolar changes characterised by granulovacuolar
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Figure 2. Photomicrographs of mice liver; H & E, 100x: (a) control liver showing normal hepatic parenchyma, hepatic lobules
and hepatocytes, (b) SM-administered mice liver (2 LD50) showing granulovacuolar degeneration and perinuclearing
clumping of cytoplasm, (c and d) pre and simultaneous treatment respectively of 100 mg/kg of quercetin with SM,
and (g and h) pre- and simultaneous treatment respectively of 200 mg/kg of quercetin with SM, showing reduced
hepatic lesions, (e and f) 2 h and 24 h post-treatment respectively of quercetin 100 mg/kg with SM, and (i and j) 2h
and 24 h post-treatment respectively of quercetin 200 mg/kg with SM, showing occasional hepatic parenchymal
degeneration.
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consisting of large polyhedral cells. The dermis
contained loose connective tissue components located
between epidermis and hypodermis [Fig. 3(a)].
Percutaneous application of SM in mice showed
some degree of epidermal destruction as evidenced
by focal keratinocyte swelling to extensive epidermal
necrosis in stratum cornium layer. Swollen cells
are seen throughout the epidermis. The spinous
cells are enlarged and vacuolated while vacuoles
are observed between epidermis and dermis. In
some places, epidermis was completely sloughed
off and dermis was completely exposed. Large
amount of inflammatory infiltrate was also observed
in the dermal region. The degenerated dermo-epidermal
area was covered by exudates composed of fibrin,
leucocytes, and RBC's. Intense inflammatory infiltrate
in the dermis reached the hypodermis. SM administration
also caused edema and ulcer [Fig. 3(b)]. Pre-
treatment 30 min or simultaneous treatment of
quercetin at doses of 100 mg/kg or 200 mg/kg with
SM administration reduced the severity of the lesions
[Figs 3(c), 3(d), 3(g) and 3(h)]. However, quercetin,
2 h or 24 h post-treatment following SM administration
did not give significant protection to the skin lesions
in comparison to pre- and simultaneous treatment
of quercetin [Figs 3(e), 3(f), 3(i) and 3(j)].
4 . DISCUSSION
Sulphur mustard is a potent alkylating agent
with electrophilic property. This results in the production
of reactive oxygen species (ROS) and oxidative
stress with depletion of cellular detoxifying thiols
including glutathione33. In this study, flavonoid quercetin
was used which is a well known antioxidant, to
reduce the toxic effects of SM19. A number of
biochemical reactions in the body generate highly
reactive oxygen species and free radicals with
unpaired electrons that may cause cellular damage.
An unpaired electron is highly unstable and reactive.
Free radicals instantaneously react with other compounds
to capture the needed electron. With the loss of
an electron, the stable molecule per se becomes
a free radical and a chain reaction is initiated34.
Quercetin and its many metabolites can neutralise
the free radicals by donating one of their electrons
thus ending the electron chain reactions35. Quercetin
is one of the most abundant flavonoids in human
diet and is reported to exhibit a wide range of
pharmacological properties36. In this study, intraperitonial
administration of quercetin significantly prevented
the SM-induced body weight loss and also protected
the changes in different oxidative stress markers
and hematological parameters.
Sulphur mustard is known to react with a wide
variety of macromolecules7. The mortality depends
upon the dose applied and the LD50 varies with the
observation period9. Our earlier reported LD50 of
SM by percutaneous route was 8.1 mg/kg and in
this study the LD50 is estimated to be 9.7 mg/kg.
Quercetin offered a dose dependent protection in
mice. A dose of 100 mg/kg of quercetin gave a
protection of two-fold compared to the protection
of eight-fold at 200 mg/kg, when the first dose of
quercetin was given simultaneously followed by
two more doses on the subsequent days. Single
dose of quercetin given simultaneously with SM
gave a protection of 3.2-fold in 100 mg/kg and 5.6-
fold in 200 mg/kg groups. In both the dose levels,
30 min pre-treatment as well as simultaneous treatments
showed higher protection than post- treatments.
The protection could be due to the direct interaction
of quercetin or its metabolites with SM intermediates
as well as its antioxidant property inside the system
to nullify the effect of free radicals generated by SM.
The body weight of animals decreased
progressively, and in some cases 50 per cent reduction
in initial body weight was observed. This was partially
due to the reduced intake of food and water as a
result of the toxic effects of SM. Generally, the
mice died within a period of 14 days after SM
application and beyond this period they survived.
At lower doses weight loss was seen up to 12 days
after SM application, and then the body weight
started improving. The protection on SM-induced
weight loss was observed only when quercetin
was administered as pre-treatment or simultaneous
treatment but not as post- treatment. Similar observation
was made in the protection of quercetin in ethanol-
induced oxidative stress20. This shows that quercetin
or its active metabolite should be available to interact
with the active metabolite of SM. If this is true,
than the two subsequent doses of quercetin given
on the next two days may not be necessary. The
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Figure 3. Photomicrographs of mice skin; H and E, 100x: (a) control skin showing normal epidermis and dermis having flattened
fused cell, dense basophilic granular cells and large polyhedral cells with well defined cell borders; (b) SM-administered
mice skin (2 LD50) showing invasion of the epidermis by acute inflammatory cells, dermo-epidermal separation,
accumulation of exudates composed of fibrinoid material and RBC's, (c and d) pre- and simultaneous treatment
respectively of 100 mg/kg of quercetin with SM, and (g and h) pre- and simultaneous treatment respectively of
200 mg/kg of quercetin with SM, showing reduction of lesions in the skin; (e and f) 2 h and 24 h post-treatment
respectively of quercetin 100 mg/kg with SM, and (i and j) 2 h and 24 h post-treatment respectively of quercetin 200
mg/kg with SM, showing lack of protection of SM-induced skin lesions.
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initial experiments were planned with the three
doses and later experiments were carried out with
the single dose of quercetin given either as 30 min
pre-treatment or simultaneous treatment. The protection
of the single dose was at par with the three doses.
A significant decrease in GSH after SM
administration is a constant finding. In the present
study, a significant decrease not only in GSH but
also in GSSG was observed. Since SM interacts
with a wide variety of biomolecules causing multiorgan
failure, decrease in GSH and GSSG is expected.
The depletion of GSH may be due to direct interaction
with sulphonium ion. The decrease in GSH and
GSSG was recovered by quercetin in a dose-dependent
manner. Pre-treatment and simultaneous treatment
significantly protected but not the post-treatment.
Quercetin's antioxidant properties are due to its
active metabolites, which usually forms in the body
by sulphation, methylation or glucuronation. The
absorbed quercetin is transported through albumin,
chiefly methylated in the 3' position and conjugated
with glucuronic acid and sulphates. Recent studies
have specified that the conjugated forms are mostly
glucurono-sulphates. These active metabolites may
be reacting with the intermediates of SM and free
radicals to minimise the toxic effects. The post-
treatments have failed because, quercetin metabolites
should be present in the body before SM binds to
the biomolecules.
Normally lipid peroxidation takes place in normal
cells to some extant and due to SM toxicity, there
is an increase in lipid peroxidation as shown by an
increase in malondialdehyde (MDA) level. The MDA
was increased in SM toxicity to 150 per cent and
this was recovered by pre-treatment or simultaneous
treatment with quercetin but not with post-treatment.
Protection was more prominent in 200 mg/kg as
compared to 100 mg/kg. This protection might be
due to the quenching of lipid peroxides by quercetin
from the cells. Quercetin also donates an electron
to the free radicals formed in the body20. Since
pre-treatment or simultaneous treatments alone could
protect SM toxicity, it appears that the initiation of
toxic effects following SM administration are immediate,
though symptoms may appear later. SM is a bifunctional
alkylating agent leading to DNA strand breaks and
cell death6. The present study shows that pre-
treatment and simultaneous treatment of quercetin,
significantly protected SM-induced DNA damage.
The authors expect that due to the antioxidant and
free radical scavenging properties of the flavonoids,
these might protect therapeutically. Hence, this
study was carried out using various time points
after application of SM and the results show that
flavonoids will be beneficial only as a pre-treatment
and not as post-treatment. SM forms sulphonium
ion in the body which is electrophilic in nature. The
flavonoids like quercetin are nucleophilic in nature
and there is a possibility of an electron transfer
from 3' OH group of quercetin to the sulphonium
ion. This is one possible reason for the protection
of quercetin as a prophylactic agent, by neutralising
the sulphonium ion.
Following percutaneous administration of SM,
the animals appear emaciated and dehydrated, resulting
in reduced blood volume. This may be the reason
of an increased hemoglobin and RBC count. SM
causes bone marrow depression and a decrease in
WBC count is expected. But no such decrease
was observed, and WBC count was unaffected or
slightly increased after SM. This is also due to the
haemoconcentration. Another reason might be that
bone marrow depression is expected at very high
toxic dose of SM. Probably at the 2 LD50 dose,
the effect of SM on haemopoitic cells is not that
prominent for the depression of bone marrow. The
present study also shows that percutaneous
administration of SM can cause lesions distal to
the site of application. Histological examination of
spleen, liver, and skin showed that quercetin can
protect SM-induced histological lesions and this
may be due to its free radical scavenging properties.
Attention is now being focused on the flavonoids
like quercetin which are pleiotropic in their effects,
and over a dozen seemingly independent biological
effects can be listed including its antioxidant property37.
SM interaction with quercetin is one such interaction
because of its neucleophilic characteristics. Quercetin
is also a safe compound as the LD50 estimated in
our establishment is more than 5.0 g/kg by the oral
and i.p routes in mice. Further studies are in progress
on various toxicological and biochemical properties
of quercetin against SM toxicity.
718
DEF SCI J, VOL. 57, NO. 5, SEPTEMBER 2007
ACKNOWLEDGEMENTS
The authors are grateful to Er. K. Sekhar, Director,
DRDE, Gwalior, for his constant encouragement.
Thanks are also due to Dr R.C. Malhotra and
Mr K. Ganesan for providing sulphur mustard.
REFERENCES
1. Ecobichon, D.J. Toxic effects of pesticides. In
Casarett and Doull's toxicology: The basic science
of poisons, Ed. 6, edited by C.D. Klaassen.
McGraw-Hill Medical Publishing Division, New
York, 2001.
2. Wormser, U. Toxicology of mustard gas. Trends
Pharmacol. Sci., 1991, 12, 164-67.
3. Smith, W.J. & Dunn, M.A. Medical defence
against blistering chemical warfare agents. Archives
of Dermatology, 1991, 127, 1207-213.
4. Eisenmenger, W.; Drasch, G.; Von Clarmann,
M. & Kretshmer, E. Clinical and morphological
findings on mustard gas [bis(2-chloro ethyl)
sulphide] poisoning. J. Forensic Sci., 1991,
36, 1688-698.
5. Momeni, A.Z.; Enschaeih, S. & Meghdadi, M.
Skin manifestations of mustard gas. A clinical
study of 535 patients exposed to mustard gas.
Archives of Dermatology, 1992, 128, 775-80.
6. Papirmeister, B.; Feister, A,J.; Robinson, S.L.
& Ford, R.O. Medical defence against mustard
gas: Toxic mechanisms and pharmacological
implications. CRC Press, Boca, Raton, 1991.
7. Somani, S.M. & Babu, S.R. Toxicodynamics of
sulphur mustard. Int. J. Clin. Pharmacol. Theor.
Toxicol., 1989, 27, 419-35.
8. Pechura, C.M. & Rall, D.P. Veterans at risk:
The health effect of mustard and lewisite. National
Academy Press, Washington, D.C., 1993.
9. Vijayaraghavan, R.; Kumar, P.; Joshi, U.; Raza,
S.K.; Lakshman Rao, P.V.; Malhotra, R.C. &
Jaiswal, D.K. Prophylactic efficacy of amifostine
and its analogue against sulphur mustard toxicity.
Toxicology, 2001, 163, 83-91.
10. Callaway, S. & Pearce, K.A. Protection against
systemic poisoning by mustard gas di(2-chloro
ethyl) sulphide by sodium thiosulphate and
thiocit in albino rat. Br. J. Pharmacol., 1958, 13,
395-99.
11. Vojvodic, V.; Milosavljevic, Z.; Bosksvic, B. &
Bojanic, N. The protective effect of different
drugs in rats poisoned by sulphur and nitrogen
mustards. Fund. Appl. Toxico., 1985, 5, S160-
S168.
12. Vijayaraghavan, R.; Sugendran, K.; Pant, S.C.;
Husain, K. & Malhotra, R.C. Dermal intoxication
of mice with bis(2-chloroethyl) sulphide and
the protective effect of flavonoids. Toxicology,
1991, 69, 35-42.
13. Dacre, J.C. & Goldman, M. Toxicology and
Pharmacology of the chemical warfare agent
sulphur Mustard. Pharmacology Reviews, 1996,
48, 290-26.
14. Sawyer, T.W.; Lundy, P.M. & Weiss, M.T.
Protective effects of an inhibitor of nitric oxide
synthase on sulphur mustard toxicity in vitro.
Toxicology, 1996, 141, 138-44.
15. Bhattacharya, R.; Lakshmana Rao, P.V.; Pant,
S.C.; Kumar, P.; Tulsawani, R.K.; Pathak, U.;
Kulkarni, A. & Vijayaraghavan, R. Protective
effects of amifostine and its analogues on sulphur
mustard toxicity in vitro and in vivo. Toxicol.
Appl. Pharmacol., 2001, 176, 24-33.
16. Vijayaraghavan, R.; Kulkarni, A.; Pant, S.C.;
Kumar, P.; Lakshmana Rao, P.V.; Gupta, N.;
Gautam, A. & Ganesan, K. Differential toxicity
of sulfur mustard administered through percutaneous,
subcutaneous and oral routes. Toxicol. Appl.
Pharmacol., 2005, 202, 180-88.
17. Vijayaraghavan, R.; Pravin, K.; Dubey, D.K.
& Ram Singh. Evaluation of CC2 as a
decontaminant in various hydrophilic and lipophilic
formulations against sulphur mustard. Biomed.
Environ. Sci., 2001, 15, 25-31.
18. Lakshmana Rao, P.V.; Vijayaraghavan, R. &
Bhaskar, A.S.B. Sulphur mustard induced DNA
719
GAUTAM, et al.: PROTECTIVE EFFECT OF QUERCETIN AGAINST SULPHUR MUSTARD–INDUCED OXIDATIVE STRESS IN MICE
damage in mice after dermal and inhalation
exposure. Toxicology, 1999, 139, 39-57.
19. Formica, J.V. & Regelson, W. Review of the
biology of quercetin and related bioflavonoids.
Food Chem. Toxicol., 1995, 33, 1061-080.
20. Molina, M.F.; Sanchez-Reus, I.; Iglesias, I. &
Benedi, J. Quercetin, a flavonoid antioxidant,
prevents and protects against ethanol-induced
oxidative stress in mouse liver. Bio. Pharm.
Bull., 2003, 26, 1398-402.
21. Alarcon de lalastra, C.; Martin, M.J. & Motilva,
V. Antiulcer and gastroprotective effects of
quercetin: A gross and histologic study.
Pharmacology Journal, 1994, 48, 56-62.
22. Kuhlmann, M.K.; Horsch, E.; Burkhardt, G.;
Wagner, M. & Kohler, H. Reduction of cisplatin
toxicity in cultured renal tubular cells by the
bioflavonoid quercetin. Archives of Toxicology,
1998, 72, 536-40.
23. Satyanarayana, P.S.; Singh, D. & Chopra, K.
Quercetin a bioflavonoid, protects against oxidative
stress-related renal dysfunction by cyclosporine
in rats. Methods Find. Exp. Clin. Pharmacol.,
2001, 23, 175-81.
24. Pavanato, A.; Tunon, M.J.; Sanchez-Campos,
S.; Marroni, C.A.; Llesuy, S.; Gonzalez-Gallego,
J. & Marroni, N. Effects of quercetin on liver
damage in rats with carbon tetrachloride-induced
cirrhosis. Dig. Dis. Sci., 2003, 48, 824-29.
25. Kostyuk, V.A. & Potapovich, A.I. Antiradical
and chelating effects in flavonoid protection
against silica-induced cell injury. Arch. Biochem.
Biophys., 1998, 355, 43-48.
26. Hisin, P.J. & Hilf, R. A fluorometric method
for for determination of oxidised and reduced
glutathione in tissues. Annals of Biochemistry,
1976, 74, 214-226.
27. Buege, J.A. & Aust, S.D. Microsomal lipid
peroxidation. Methods in Enzymolology, 1978,
52, 303-06.
28. McConkey, D.J.; Hartzell, P.; Duddy, S.K.; Hakansson,
H. & Orrenius, S. 2,3,7,8- tetradichlorobenzo-
p-dioxin (TCDD) kills immature thymocytes
by calcium mediated endonuclease activation.
Science, 1988, 242, 256-59.
29. Burton, K. A study of the condition and mechanism
of the diphenylamine reaction for the colorimetric
estimation of deoxyribonucleic acid. Biochemistry
Journal, 1956, 62, 315-23.
30. Wyllie, A.H. Glucocorticoid induced thymocyte
apoptosis is associated with endonulease activation.
Nature, 1980, 284, 555-56.
31. McMannus, J.F.A. & Mowry, R.W. General
methods for study of the cell and it's structure.
In Staining methods: Histologic and Histochemistry,
edited by P.B. Hoeber, Harper, New York, 1965.
pp. 73-90.
32. Gad, S.C. & Weil, C.S. Statistics for toxicologists.
In Principles and methods of toxicology, Ed. 2,
edited by A.W. Hayes. Raven Press, New York,
1989. pp. 463-67.
33. Naghi, M.R. Sulphur mustard intoxication oxidative
stress and antioxidant. Military Medicine, 2002,
167, 573-75.
34. Ray, G. & Hussain, S.A. Oxidants antioxidants
and carcinogenesis. Ind. J. Exp. Biol., 2002,
40, 1213-232.
35. Manach, C.; Morand, C.; Crepsy, V.; Demigne,
C.; Texier, O.; Regerat, F. & Remesy, C. Quercetin
is recovered in human plasma as conjugated
derivatives, which retain antioxidant properties.
FEBS Letters, 1998, 426, 331-36.
36. Hollman, P.C.H.; Trip, J.M.P.V.; Baysman,
M.N.C.P.; Cagg, M.S.V.D.; Mengelers, M.J.B.;
Vries, J.H.M.D. & Katan, M.B. Relative
bioavailability of the antioxidant flavonoid quercetin
from various food in man. FEBS Letters, 1997,
418, 152-56.
37. Candlish, J.K. & Das, N.P. Antioxidants in
food and chronic degenerative disease. Biomed.
Environ. Sci., 1996, 9, 117-23.
720
DEF SCI J, VOL. 57, NO. 5, SEPTEMBER 2007
Contributors
 
Mr H.T. Satish Kumar obtained his MLISc and BEd from Karnatak University,
Dharwad. He joined DRDE, Gwalior, in 2002 as a Senior Technical Assistant. His
area of work is histopathology.
Ms Seema Singh obtained her BSc (Life Sciences) from the Purvanchal University,
Varanasi. She joined DRDE, Gwalior, in 2003 as Senior Technical Assistant in the
Division of Pharmacology and Toxicology. Her areas of research include: Safety
evaluation of various toxicants and development of antidotes against chemical
warfare agents.
Dr Om Kumar obtained his MSc (Biochemistry) from Indian Veterinary Research
Institute, Izatnagar and PhD from Jiwaji University, Gwalior. He joined Defence
Research Laboratory (DRL), Tezpur in 1989 as Scientist B. At present, he is
working as Scientist E at the DRDE, Gwalior, on the evaluation of toxicity of
chemical warfare agents, and development of detection systems and antidotes
for plant toxins. He has published 25 research papers in various national/international
journals.
Dr R. Vijayaraghavan obtained his MSc (Pharmacology) from the JIPMER, Pondicherry,
and PhD from the Jiwaji University, Gwalior. He worked as a Visiting Research
Associate at the University of Pittsburg, USA, during 1991-1993. Currently, he
is Associate Director of DRDE, Gwalior. His areas of research include: Safety
evaluation of chemicals and development of antidotes against chemical warfare
agents. He has more than 100 research papers published in various national/
international journals.
Dr S.C. Pant obtained his PhD in Zoology from Kumaon University, Nainital.  He
joined  Gwalior in 1983 and presently he is Scientist 'F'. His areas of work are:
Toxicologic pathology, histochemistry and immunohistochemistry. He has about
30 publications in national/international journals.
Ms Anshoo Gautam obtained her MSc (Biochemistry) from the B.R. Ambedker
University, Agra. She joined Defence Research and Development Establishment
(DRDE), Gwalior, as Junior Research Fellow, and presently, working as Senior
Research Fellow in the Division of Pharmacology and Toxicology. She is working
on the biochemical changes induced by chemical warfare agents and screening
of antidote for her doctoral thesis.
